Silverarc Capital Management’s Ovid Therapeutics OVID Stock Holding History

Silverarc Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.22M	Buy	+1,000,000	New	+$1.79M	0.23%	58

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Silverarc Capital Management's OVID Position: Q1 2026 in Review

Silverarc Capital Management opened a new position in Ovid Therapeutics (OVID) in Q1 2026: 1,000,000 shares worth $2.22M. The stake represents 0.23% of the portfolio and ranks #58 among its holdings.

103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Silverarc Capital Management held 1,000,000 shares of Ovid Therapeutics worth $2.22M as of Q1 2026.
Ovid Therapeutics was a new Silverarc Capital Management position in Q1 2026.
Ovid Therapeutics made up 0.23% of Silverarc Capital Management's portfolio in Q1 2026, its #58 holding.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.